This report was first published by Endpoints News. To see the original version, click here
Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month.
The California drugmaker is dishing out $80 million upfront for GH31, a MAT2A-targeted synthetic lethality drug for select solid tumors. MAT2A plays a role in metabolic regulation and can be overexpressed in cancer cells.
您已阅读15%（475字），剩余85%（2704字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。